1. Ahmadian M., Suh J.M., Hah N., Liddle C., Atkins A.R., Downes M.,Evans R.M.: PPARγ signaling and metabolism: the good, the bad andthe future. Nat. Med., 2013; 19: 557–566
2. Akinci B., Onay H., Demir T., Ozen S., Kayserili H., Akinci G., NurB., Tuysuz B., Nuri Ozbek M., Gungor A., Yildirim Simsir I., Altay C.,Demir L., Simsek E., Atmaca M. i wsp.: Natural history of congenitalgeneralized lipodystrophy: A nationwide study from Turkey. J. Clin.Endocrinol. Metab., 2016; 101: 2759–2767
3. Albert J.S., Yerges-Armstrong L.M., Horenstein R.B., PollinT.I., Sreenivasan U.T., Chai S., Blaner W.S., Snitker S., O’ConnellJ.R., Gong D.W., Breyer R.J. 3rd, Ryan A.S., McLenithan J.C., ShuldinerA.R., SztalrydC., Damcott C.M.: Null mutation in hormonesensitivelipase gene and risk of type 2 diabetes. N. Engl. J. Med.,2014; 370: 2307–2315
4. Alcantara D., Elmslie F., Tetreault M., Bareke E., Hartley T.; Care4RareConsortium, Majewski J., Boycott K., Innes A.M., Dyment D.A.,O’Driscoll M.: SHORT syndrome due to a novel de novo mutation inPRKCE (protein kinase Cɛ) impairing TORC2-dependent AKT activation.Hum. Mol. Genet., 2017; 26: 3713–3721
5. Altomare D.A., Khaled A.R.: Homeostasis and the importance fora balance between AKT/mTOR activity and intracellular signaling.Curr. Med. Chem. 2012; 19: 3748–3762